Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 10/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172904 | 1.00 | KCNQ2 (0.46) | KCNQ2L3MBTL1KMT2AMEN1TRPV1 | |
| SCHEMBL1172329 | 0.86 | KCNQ2 (0.43) | KCNQ2KMT2AMEN1TRPV1GAA | |
| SCHEMBL30794979 | 0.86 | KCNQ2 (0.43) | KCNQ2KMT2AMEN1TRPV1GAA | |
| SCHEMBL1172488 | 0.86 | KCNQ2 (0.49) | KCNQ2L3MBTL1KMT2AMEN1TRPV1 | |
| SCHEMBL30796321 | 0.86 | KCNQ2 (0.49) | KCNQ2L3MBTL1KMT2AMEN1TRPV1 | |
| SCHEMBL30795463 | 0.85 | KCNQ2 (0.44) | KCNQ2KMT2AMEN1TRPV1GAA | |
| SCHEMBL1172601 | 0.85 | KCNQ2 (0.44) | KCNQ2KMT2AMEN1TRPV1GAA | |
| SCHEMBL30796352 | 0.83 | KCNQ2 (0.52) | KCNQ2KMT2ATRPV1 | |
| SCHEMBL13810507 | 0.83 | KCNQ2 (0.45) | KCNQ2L3MBTL1KMT2AMEN1TRPV1 | |
| SCHEMBL1172456 | 0.83 | KCNQ2 (0.52) | KCNQ2KMT2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |